Meitheal Pharmaceuticals at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Meitheal Pharmaceuticals brings 2 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1342. Its program centres on intravenous fosfomycin, branded Contepo, covering unmet needs and clinical evidence. A post hoc analysis of the ZEUS trial describes when low potassium appears, how severe it gets and how long it lasts in adults treated for complicated urinary tract infection.
| Organization | IDWeek 2026 Attendance |
|---|---|
Meitheal Pharmaceuticals Chicago, IL | |
Chicago company, founded 2017, that develops and sells generic injectable medicines, including anti-infectives, and has added fertility, biologic and branded products. | Booth Exhibiting at Booth 1342 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 11:15am–11:35am CONTEPO® (IV fosfomycin): Exploring unmet needs and clinical evidence Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Timing, Severity, and Duration of Hypokalemia in Adults with Complicated Urinary Tract Infection Treated with Intravenous Fosfomycin (Contepo): Post Hoc Analysis of the ZEUS Trial |
Instantly find 20 buyers from Meitheal Pharmaceuticals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction